Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis

References

• Saha A, Samadder A, Nandi S. Stem cell therapy in combination with naturopathy: current progressive management of diabetes and associated complications. Curr Top Med Chem. 2023;23(8):1–14. doi: 10.2174/1568026623666221201150933.
   Web of Science ®Google Scholar
• Kumari K, Kumar R, Memon A, et al. Treatment with testosterone therapy in type 2 diabetic hypogonadal adult males: a systematic review and Meta-Analysis. Clin Pract. 2023; 13(2):454–469. doi: 10.3390/clinpract13020041.
   PubMed Web of Science ®Google Scholar
• Kumar S, Khatri M, Memon RA, et al. Effects of testosterone therapy in adult males with hypogonadism and T2DM: a meta-analysis and systematic review. Diabetes Metab Syndr. 2022;16(8):102588. doi: 10.1016/j.dsx.2022.102588.
   PubMedGoogle Scholar
• ‘Diabetes.‘. World Health Organization, www.who.int/news-room/fact-sheets/detail/diabetes. Accessed 10 July 2023.
   Google Scholar
• Yu J, Lee SH, Kim MK. Recent updates to clinical practice guidelines for diabetes mellitus. Endocrinol Metab. 2022; 37(1):26–37. doi: 10.3803/EnM.2022.105.
   Google Scholar
• Alhindi Y, Avery A. The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: a systematic review and network meta-analysis. Contemp Clin Trials Commun. 2022; 28:100944. doi: 10.1016/j.conctc.2022.100944.
   PubMed Web of Science ®Google Scholar
• Rubino DM, Greenway FL, Khalid U, STEP 8 Investigators., et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022; 327(2):138–150. doi: 10.1001/jama.2021.23619.
   PubMed Web of Science ®Google Scholar
• Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022;23(3):521–539. doi: 10.1007/s11154-021-09699-1.
   PubMed Web of Science ®Google Scholar
• Jalaludin MY, Deeb A, Zeitler P, et al. Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin. Pediatr Diabetes. 2022;23(2):183–193. doi: 10.1111/pedi.13282.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the european association for the study of diabetes. Diabetes Care. 2015; 38(1):140–149. doi: 10.2337/dc14-2441.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC,, et al. The cochrane collaboration’s tool for assessing risk of bias in randomized trials. BMJ. 2011; 343:d5928. doi: 10.1136/bmj.d5928.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi: 10.1136/bmj.327.7414.557.
   PubMed Web of Science ®Google Scholar
• Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017; 5(5):341–354. doi: 10.1016/S2213-8587(17)30092-X.
   PubMed Web of Science ®Google Scholar
• Ji L, Dong X, Li Y, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab. 2021;23(2):404–414. doi: 10.1111/dom.14232.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Carr MC, Stewart M, et al. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014;37(10):2723–2730. doi: 10.2337/dc13-2855.
   PubMed Web of Science ®Google Scholar
• Stolar MW, Grimm M, Chen S. Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes. Diabetes Metab Syndr Obes. 2013; 6:435–444. doi: 10.2147/DMSO.S48837.
   PubMedGoogle Scholar
• Nauck MA, Kahle M, Baranov O, et al. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab. 2017; 19(2):200–207. doi: 10.1111/dom.12802.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. Eur J Intern Med. 2012;23(2):126–131. doi: 10.1016/j.ejim.2011.10.007.
   PubMed Web of Science ®Google Scholar
• Li S, Li H, Wang R, et al. The effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus. Eur Rev Med Pharmacol Sci. 2017; 21(15):3490–3495.
   PubMed Web of Science ®Google Scholar
• Kodera R, Shikata K, Nakamura A, et al. The glucose-lowering efficacy of sitagliptin in obese Japanese patients with type 2 diabetes. Intern Med. 2017;56(6):605–613. doi: 10.2169/internalmedicine.56.7428.
   PubMed Web of Science ®Google Scholar
• Dai D, Mao Y, Jin H, et al. Efficacy and hypoglycemic risk of sitagliptin in obese/overweight patients with type 2 diabetes compared with GLP-1 receptor agonists: a meta-analysis. Medicine (Baltimore). 2019;98(36):e17081. doi: 10.1097/MD.0000000000017081.
   PubMed Web of Science ®Google Scholar
• Buse JB, Bode BW, Mertens A, et al. Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial. BMJ Open Diabetes Res Care. 2020; 8(2):e001649. doi: 10.1136/bmjdrc-2020-001649.
   PubMed Web of Science ®Google Scholar
• Lavernia F, Blonde L. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo. Postgrad Med. 2020; 132(sup2):15–25. doi: 10.1080/00325481.2020.1798638.
   PubMedGoogle Scholar
• Shi FH, Li H, Cui M, et al. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2018; 9:576. doi: 10.3389/fphar.2018.00576.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019; 321(15):1466–1480. doi: 10.1001/jama.2019.2942.
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi: 10.1056/NEJMoa2032183.
   PubMed Web of Science ®Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425. doi: 10.1001/jama.2021.3224.
   PubMed Web of Science ®Google Scholar
• Miles KE, Kerr JL. Semaglutide for the treatment of type 2 diabetes mellitus. J Pharm Technol. 2018;34(6):281–289. doi: 10.1177/8755122518790925.
   PubMed Web of Science ®Google Scholar